# AstraZeneca reports positive Phase III EMERALD-3 results in unresectable liver cancer

- Link: https://www.directorstalkinterviews.com/astrazeneca-reports-positive-phase-iii-emerald-3-results-in-unresectable-liver-cancer/4121247654
- Published: 2026-04-02T07:23:28+01:00
- Author: Amilia Stone

Positive high-level results from the EMERALD-3 Phase III trial showed **[AstraZeneca plc](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l)**(
[LON:AZN](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l))_
Imfinzi_ (durvalumab) in combination with _Imjudo_ (tremelimumab), lenvatinib and
transarterial chemoembolisation (TACE) demonstrated a statistically significant 
and clinically meaningful improvement in the primary endpoint of progression-free
survival (PFS) versus TACE alone for patients with unresectable hepatocellular carcinoma(
HCC) eligible for embolisation.

At this interim analysis for overall survival (OS), a key secondary endpoint, this
combination also demonstrated a trend toward OS improvement versus TACE alone.

Patients in the investigational arms were treated with the STRIDE regimen (Single
Tremelimumab Regular Interval Durvalumab), with or without lenvatinib, before TACE,
and then alongside TACE.

Although not formally tested at this time, data for the treatment arm evaluating
the STRIDE regimen plus TACE versus TACE alone showed strong trends toward improved
PFS and OS. The trial will continue to follow OS and other key secondary endpoints
in both investigational arms.

HCC is the most common type of liver cancer.^(1) In 2026, more than 200,000 patients
with HCC will be eligible for embolisation, a standard-of-care procedure that blocks
the blood supply to the tumour and can also deliver chemotherapy directly to the
liver.^(2-4) However, most patients who receive embolisation experience disease 
progression or recurrence within six to ten months.^(5)

> **Ghassan Abou-Alfa, MD, JD, MBA, PhD(hc), Attending Physician, Professor of Medicine
> at Memorial Sloan Kettering Cancer Center, and principal investigator in the trial
> said,** “Dual immunotherapy with durvalumab and tremelimumab in the STRIDE regimen
> represents a meaningful advance for patients with embolisation-eligible liver 
> cancer, who currently lack systemic treatment options to keep their cancer from
> progressing or recurring, with a trend of improving survival. EMERALD‑3 shows 
> we can now significantly reduce the risk of disease progression with STRIDE as
> the immunotherapy backbone alongside lenvatinib and TACE.”

> **Susan Galbraith, Executive Vice President, Oncology Haematology R&D, AstraZeneca,
> said:** “EMERALD‑3 now shows that bringing the dual immunotherapy STRIDE regimen
> earlier, alongside TACE and lenvatinib, can further improve outcomes in earlier‑
> stage liver cancer. This builds on the HIMALAYA Phase III trial data in patients
> with advanced, unresectable disease, where the STRIDE regimen has already demonstrated
> durable overall survival benefit. We are discussing these positive data with global
> regulatory authorities while awaiting the final results from the key secondary
> endpoints.”

The safety profile for each combination was consistent with the known profiles of
each medicine, and there were no new safety findings.

These data will be presented at a forthcoming medical meeting and shared with global
regulatory authorities.

**References**

1.   American Cancer Society. What is Liver Cancer? Available at: https://www.cancer.
org/cancer/types/liver-cancer/about/what-is-liver-cancer.html. Accessed April 2026.

2.   AstraZeneca PLC. Investor Relations Epidemiology Spreadsheet. Top 8 Countries.
Available at:

https://www.astrazeneca.com/investor-relations.html. Accessed April 2026.

3.   National Cancer Institute. Embolization. Available at: https://www.cancer.gov/
publications/dictionaries/cancer-terms/def/embolization. Accessed April 2026.   

4.   Kotsifa E, _et al._ Transarterial Chemoembolization for Hepatocellular Carcinoma:
Why, When, How? _J Pers Med._2022;12(3):436.

5.   Meyer T, _et al._ Sorafenib in combination with transarterial chemoembolisation
in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-
controlled, double-blind, phase 3 trial. _Lancet Gastroenterol Hepatol._ 2017;2(
8):565-575.

Share on:
